Albireo caps a big week with back-to-back approvals in the US/EU for the first drug to treat a severe liver disease
Albireo $ALBO CEO Ron Cooper is getting his long-awaited shot at marketing the first drug approved for pruritus in all subtypes of progressive familial intrahepatic cholestasis.
The biotech put out word Tuesday afternoon that the FDA came through with the approval right on deadline, something that had been expected since the agency handed the company a priority review for the drug. That now gives them a green light to see how much of a head start they can get before Mirum finds out about the ultimate fate of its own PFIC program.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.